丁一 1,2,3 , 高本见 1,2,3 , 刘永发 1,2,3 , 杨小李 1,2,3 , 陈跃 3,4 , 李波 1,2,3
  • 1. Department of General Surgery/Hepatopancreatobiliary Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P. R. China;
  • 2. Academician (Expert) Workstation of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P. R. China;
  • 3. Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan 646000, P. R. China;
  • 4. Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P. R. China;
陈跃, Email: chenyue5523@126.com; 李波, Email: liboer2002@126.com
Export PDF Favorites Scan Get Citation

Objective To evaluate the efficacy and safety of 177Lu-FAP-2286 radioligand therapy (RLT) in advanced digestive system malignancies and explore its clinical potential as a novel targeted therapeutic approach. Methods This retrospective analysis examined clinical data from 19 patients with advanced digestive system tumors who received 177Lu-FAP-2286 treatment at the Affiliated Hospital of Southwest Medical University between June 2023 and December 2024. Treatment response was assessed using response evaluation criteria in solid tumor (RECIST) 1.1 criteria and modified PERCIST(PET response criteria in solid tumor, PERCIST) 1.0 guidelines. Adverse events (AEs) were graded according to CTCAE v5.0. Results At the last follow-up, consistent therapeutic outcomes were observed between RECIST 1.1 and PERCIST 1.0 evaluations, we observed 2 cases of partial response / partial metabolic response, 4 cases of stable disease / stable metabolic disease, and 13 cases of progressive disease / progressive metabolic disease, demonstrating an objective response rate of 10.5% (2/19) and disease control rate of 31.6% (6/19). Post-treatment monitoring revealed 7 AEs of grade 2 and 1 AE of grade 1, with no occurrence of grade 3–4 haematological or hepatorenal toxicities. Common treatment-related symptoms, including nausea, decreased appetite, and fatigue, showed spontaneous resolution over time. Conclusions Preliminary findings indicate that 177Lu-FAP-2286 exhibits favourable safety and tolerability in patients with advanced digestive system malignancies while demonstrating efficacy in controlling disease progression for a subset of patients. However, multicenter prospective studies with larger cohorts are warranted to further validate its long-term efficacy and identify clinical characteristics of digestive system malignancy patients who may benefit.

Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved